•$博士伦 (BLCO.US)$JP摩根分析师罗比·马库斯initiated coverage鲍许+隆伯姆公司的中立评级和$20 price target. Bausch + Lomb has one of the broadest portfolios in the ophthalmology space as the only company with solutions across contact lenses, consumer health, ophthalmic surgical, and ophthalmic pharmaceuticals, Marcus tells investors in a research note. However, it has "lagged in certain end markets and faces competition from several larger companies," says the analyst. Marcus wants to see more tangible improvements in growth and share capture before getting positive on the stock.